InMed Pharmaceuticals announces new preclinical data on INM-901
Preclinical Findings: InMed Pharmaceuticals' INM-901 shows promise in reducing inflammation related to Alzheimer's disease, as demonstrated by significant reductions in pro-inflammatory cytokines and inflammasome markers in ex vivo models.
Potential Applications: The treatment's effectiveness in lowering inflammatory markers independently of amyloid-beta or tau pathology suggests its potential use in addressing other dementia-related diseases.
Trade with 70% Backtested Accuracy
Analyst Views on INM
About INM
About the author
Intuit Shares Rise: 20 Stocks Making Moves in Premarket Trading
Intuit's Financial Performance: Intuit Inc. reported better-than-expected first-quarter results, with revenue of approximately $3.89 billion and adjusted earnings of $3.34 per share, leading to a 3.2% increase in share price during pre-market trading.
Second-Quarter Expectations: The company anticipates second-quarter revenue growth of 14% to 15% and adjusted earnings between $3.63 and $3.68 per share, which is below analyst estimates.
Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, including Nuvve Holding Corp, which surged 49.4%, and Enviri Corp, which gained 31.5% after announcing a major sale.
Declines in Other Stocks: Conversely, Pasithea Therapeutics Corp experienced a notable decline of 25.3% following the release of interim trial data, alongside other stocks like Safe & Green Holdings Corp and VisionSys AI Inc, which also saw significant drops.
Nvidia Shares Rise Over 5%; Check Out 20 Stocks Making Moves in Premarket Trading
NVIDIA's Strong Performance: NVIDIA Corp's shares rose 5.2% in pre-market trading after reporting a 62% year-over-year revenue increase to $57.0 billion for Q3, surpassing expectations with a strong revenue forecast for the current quarter.
Notable Gainers: Several stocks saw significant pre-market gains, including Sonder Holdings Inc (+138.8%), Inspire Veterinary Partners Inc (+60.3%), and Cerence Inc (+29.2%), following positive financial results or forecasts.
Major Losers: WeShop Holdings Limited experienced a sharp decline of 38.8% in pre-market trading after a previous surge, while other notable losers included Brera Holdings PLC (-35.5%) and Meihua International Medical Tech Co Ltd (-23.8%).
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies reporting better-than-expected financial results while others faced significant declines.
What Factors Contributed to InMed's (INM) 22% Rise in After-Hours Trading?
Stock Performance: InMed Pharmaceuticals Inc. shares rose 21.98% in after-hours trading to $1.50, despite a 15.75% drop during the regular session, closing at $1.23.
Research Milestone: The company successfully completed pharmacokinetic studies for its Alzheimer’s candidate INM-901 in large animal models, demonstrating strong bioavailability and therapeutic exposure.
Regulatory Plans: InMed is preparing for Investigational New Drug (IND) submission by conducting dose-ranging studies and a pre-IND meeting with the FDA, alongside additional development for production scaling.
Financial Overview: As of September 30, InMed reported $9.3 million in cash, sufficient to fund operations into Q4 2026, although its stock has declined 74.38% this year, with a market cap of $3.45 million.
InMed Scheduled to Present at the Life Sciences Virtual Investor Forum on September 18, 2025
Event Announcement: InMed Pharmaceuticals Inc. will present at the Life Sciences Virtual Investor Forum on September 18, 2025, where CEO Eric A. Adams will discuss updates on the company's drug pipeline, including recent data on INM-901 for Alzheimer's treatment.
Interactive Participation: The event will allow real-time questions from investors, with an archived webcast available for those unable to attend live. Pre-registration is recommended for a smoother experience.
Agenda for Life Science Virtual Investor Forum Set for September 18th
Event Announcement: The Life Science Virtual Investor Forum is scheduled for September 18, 2025, co-hosted by Zacks SCR, inviting individual and institutional investors to attend presentations and one-on-one meetings with company management.
Participation Details: Investors are encouraged to pre-register and perform an online system check for a smoother experience, with no cost to attend live presentations or schedule meetings.
Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data
Stock Performance: Cognition Therapeutics Inc (CGTX) saw a significant stock increase of 20.82% during regular trading hours, followed by an additional 12.10% rise in after-hours trading, reaching $0.45.
Drug Trial Success: The surge in stock price is linked to promising results from its Alzheimer's drug, Zervimesine, which achieved a 95% efficacy rate in its Phase 2 trial and reached a 50% enrollment milestone.
Intuit Shares Rise: 20 Stocks Making Moves in Premarket Trading
Intuit's Financial Performance: Intuit Inc. reported better-than-expected first-quarter results, with revenue of approximately $3.89 billion and adjusted earnings of $3.34 per share, leading to a 3.2% increase in share price during pre-market trading.
Second-Quarter Expectations: The company anticipates second-quarter revenue growth of 14% to 15% and adjusted earnings between $3.63 and $3.68 per share, which is below analyst estimates.
Pre-Market Stock Movements: Several stocks saw significant pre-market trading movements, including Nuvve Holding Corp, which surged 49.4%, and Enviri Corp, which gained 31.5% after announcing a major sale.
Declines in Other Stocks: Conversely, Pasithea Therapeutics Corp experienced a notable decline of 25.3% following the release of interim trial data, alongside other stocks like Safe & Green Holdings Corp and VisionSys AI Inc, which also saw significant drops.
Nvidia Shares Rise Over 5%; Check Out 20 Stocks Making Moves in Premarket Trading
NVIDIA's Strong Performance: NVIDIA Corp's shares rose 5.2% in pre-market trading after reporting a 62% year-over-year revenue increase to $57.0 billion for Q3, surpassing expectations with a strong revenue forecast for the current quarter.
Notable Gainers: Several stocks saw significant pre-market gains, including Sonder Holdings Inc (+138.8%), Inspire Veterinary Partners Inc (+60.3%), and Cerence Inc (+29.2%), following positive financial results or forecasts.
Major Losers: WeShop Holdings Limited experienced a sharp decline of 38.8% in pre-market trading after a previous surge, while other notable losers included Brera Holdings PLC (-35.5%) and Meihua International Medical Tech Co Ltd (-23.8%).
Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies reporting better-than-expected financial results while others faced significant declines.
What Factors Contributed to InMed's (INM) 22% Rise in After-Hours Trading?
Stock Performance: InMed Pharmaceuticals Inc. shares rose 21.98% in after-hours trading to $1.50, despite a 15.75% drop during the regular session, closing at $1.23.
Research Milestone: The company successfully completed pharmacokinetic studies for its Alzheimer’s candidate INM-901 in large animal models, demonstrating strong bioavailability and therapeutic exposure.
Regulatory Plans: InMed is preparing for Investigational New Drug (IND) submission by conducting dose-ranging studies and a pre-IND meeting with the FDA, alongside additional development for production scaling.
Financial Overview: As of September 30, InMed reported $9.3 million in cash, sufficient to fund operations into Q4 2026, although its stock has declined 74.38% this year, with a market cap of $3.45 million.
InMed Scheduled to Present at the Life Sciences Virtual Investor Forum on September 18, 2025
Event Announcement: InMed Pharmaceuticals Inc. will present at the Life Sciences Virtual Investor Forum on September 18, 2025, where CEO Eric A. Adams will discuss updates on the company's drug pipeline, including recent data on INM-901 for Alzheimer's treatment.
Interactive Participation: The event will allow real-time questions from investors, with an archived webcast available for those unable to attend live. Pre-registration is recommended for a smoother experience.
Agenda for Life Science Virtual Investor Forum Set for September 18th
Event Announcement: The Life Science Virtual Investor Forum is scheduled for September 18, 2025, co-hosted by Zacks SCR, inviting individual and institutional investors to attend presentations and one-on-one meetings with company management.
Participation Details: Investors are encouraged to pre-register and perform an online system check for a smoother experience, with no cost to attend live presentations or schedule meetings.
Cognition Therapeutics Shares Jump 12% After Hours Following Encouraging Phase 2 Alzheimer's Trial Data
Stock Performance: Cognition Therapeutics Inc (CGTX) saw a significant stock increase of 20.82% during regular trading hours, followed by an additional 12.10% rise in after-hours trading, reaching $0.45.
Drug Trial Success: The surge in stock price is linked to promising results from its Alzheimer's drug, Zervimesine, which achieved a 95% efficacy rate in its Phase 2 trial and reached a 50% enrollment milestone.
